Cocaine Exposure in the Womb: The Brain Structure Is Intact but Development Is Off Track
Philadelphia, PA, September 25, 2013
Says a new
study in Biological Psychiatry
Says a new study in Biological Psychiatry
Prenatal cocaine exposure
affects both behavior and brain. Animal studies have shown that exposure to
cocaine during in utero development causes numerous disruptions in normal brain
development and negatively affects behavior from birth and into adulthood.
For ethical reasons, similar studies in humans have been more limited but some research has shown that children exposed prenatally to cocaine have impairments in attention, control, stress, emotion regulation, and memory. Research also suggests that such children may be more predisposed to initiate substance use.
Since adolescence is the typical period in life when substance use begins, researchers from the Yale University School of Medicine, led by Dr. Rajita Sinha, conducted a study to evaluate the gray matter differences and likelihood of substance use in adolescents who were cocaine-exposed prenatally versus those who were not.
To do this, they recruited 42 adolescents between the ages of 14 and 17, exposed in utero, who are part of a long-term cohort that have been followed since birth. They also studied 21 non-cocaine-exposed adolescents for comparison. All of the participants underwent structural neuroimaging scans and answered questions about their use of all kinds of illegal drugs, in addition to submitting urine samples for toxicology analyses.
What they found was concerning, but exactly what they had hypothesized. The adolescents with prenatal cocaine exposure had lower gray matter volume in key brain regions involved in emotion, reward, memory, and executive function, compared with non-exposed adolescents.
Gray matter volume was also associated with initiation of substance use. Astoundingly, each 1-mL decrease in gray matter volume increased the probability of initiating substance use by 69.6% to 83.6% depending upon the region of the brain.
"This study may have an important message for pregnant women who use cocaine. It appears that we need to take a long-term perspective on the risks associated with prenatal exposure to cocaine: people whose brains may appear structurally typical at birth may develop abnormally," said Dr. John Krystal, Editor of Biological Psychiatry. "While the significance of these structural changes is not clear, they merit further study."
Gray matter is the part of the nervous system that processes information, and deficits in gray matter are documented in many other disorders, including schizophrenia, anorexia, and childhood attention-deficit/hyperactivity disorder. It is important to note that, as part of the study criteria, these participants had no significant medical or mental illness and differed only in whether their mothers had used cocaine while pregnant.
"Thus, for the first time in children we see how mothers' in-utero cocaine use may translate to brain changes in the offspring that impact cognition, mood and health of the affected offspring later in life," said Sinha. "One can speculate that in the future, with additional validation, such specific brain alterations may serve as biomarkers of risk that can be targeted to prevent drug use and abuse."
The article is "Prenatal Cocaine Exposure and Gray Matter Volume in Adolescent Boys and Girls: Relationship to Substance Use Initiation" by Kenneth Rando, Tara M. Chaplin, Marc N. Potenza, Linda Mayes, and Rajita Sinha (doi: 10.1016/j.biopsych.2013.04.030). The article appears in Biological Psychiatry, Volume 74, Issue 7 (October 1, 2013), published by Elsevier.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Rajita Sinha at +1 203 737 5805 or Rajita.Sinha@yale.edu.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 135 Psychiatry titles and 13th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2012 Impact Factor score for Biological Psychiatry is 9.247.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 214 648 0880